Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods, devices and systems for pulmonary delivery of active agents

A pharmacological active agent and lung technology, applied in aerosol delivery, organic active ingredients, muscular system diseases, etc., can solve problems such as limitations, difficult quantification, and difficult controllable administration

Active Publication Date: 2020-07-03
SYQE医药有限公司
View PDF18 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Natural substances, such as plant materials, provide a large number of pharmaceutically active agents that can provide a wide range of therapeutic and other beneficial effects; however, many uses of such substances for direct pharmacological purposes are due to technical and cultural reasons has been limited mainly because of the reluctance of professionals and pharmacologists, who are aware of the beneficial effects of these substances, to prescribe natural substances, since the active agents contained within them are difficult to quantify, and therefore difficult to controllably administer
[0005] In addition to the ability to control with precision and consistency the amount of evaporation of a pharmaceutically active agent derived from natural botanical substances, the dosing and regimen issues associated with current methods for pulmonary delivery of such agents are often addressed through user-based Subjective trial and error to resolve, as measuring pharmacokinetic and pharmacodynamic parameters remains beyond the reach of most users

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods, devices and systems for pulmonary delivery of active agents
  • Methods, devices and systems for pulmonary delivery of active agents
  • Methods, devices and systems for pulmonary delivery of active agents

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 4

[0675] Pulmonary Delivery Protocol

[0676] The following are examples of uses of the methods, apparatus and systems presented herein according to some embodiments of the present disclosure.

[0677] An MDI device, such as Figure 16 and / or as described in 17, loaded with a plurality of pre-weighted cartridges, each containing a substance comprising one or more volatilizable pharmaceutically active agents. As described above, the MDI is pre-calibrated and preset to deliver a predetermined vaporized amount of the pharmaceutically active agent based on PK / PD data obtained for a particular patient population and / or PK effects.

[0678] For example as above in Figure 9 This system, described in , is preloaded with personal information about the patient (e.g., PK variables) and his or her medical condition and history, data about the scheduled vaporized volume and time interval for pulmonary delivery of the agent (dosing and regimen); data on a preselected pharmacokinetic profi...

Embodiment 5

[0691] Treatment with combinations of active agents

[0692] According to some embodiments of the present disclosure, active agent combination therapy may include active agents that provide a synergistic effect; active agents that provide the same effect but each have different advantages or disadvantages; one active agent that enhances or weakens another or other Active (eg, altering each other's effective therapeutic window or therapeutic index); active agents that provide contradictory effects.

[0693] According to some embodiments, potential benefits of combination therapy, such as achieved through use of the presently described devices, include, but are not limited to, precise dosing of each of the multiple active agents as well as each inhalation event and between and / or inhalation of the active agents. Exact scaling between events.

[0694] For example, in some embodiments, the ability to deliver multiple regimens involving different agents and / or different dosing int...

Embodiment 6

[0711] User / physician interface input and output

[0712] The following is a presentation of user interface input categories according to some embodiments of the present disclosure.

[0713] Typically and optionally, the user interface may provide feedback from the user indicating one or more of the following:

[0714] 1. User identity;

[0715] 2. Perceived or measured treatment / dose / regime treatment or adverse effects;

[0716] 3. Instructions / requests from the user regarding timing and / or acceptable and / or expected treatments or adverse effects.

[0717] User identity may be monitored by user response (password, pattern entry or other challenge request) or by biometric means (facial and / or voice recognition, fingerprint, retinal scan). Usage activity (device hold / grip, inhalation, inactivity) can be monitored through thermal sensing, charge and acceleration measurements.

[0718] Perceived or measured treatment or side effects may include one or more of treatment relate...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
thicknessaaaaaaaaaa
sizeaaaaaaaaaa
electrical resistivityaaaaaaaaaa
Login to View More

Abstract

The present invention provides a system comprising a metered dose inhaler device for pulmonary delivery to a subject of at least one predetermined vaporization of at least one pharmacologically active agent in a plant material amount, wherein evaporation is achieved by controllably heating said plant material so as to evaporate a predetermined amount of said agent; said system further comprising a controller in communication with said inhaler device configured to be based on said Said predetermined vaporized amount is controlled in accordance with a data indication of at least one pharmacodynamic effect induced by said agent in said subject.

Description

[0001] Related application [0002] This application claims U.S. Patent Provisional Application No. 62 / 019,225, filed June 30, 2014 (Attorney Docket No. 59426); U.S. Patent Provisional Application No. 62 / 035,588, filed August 11, 2014 ( Attorney Docket No. 59871); U.S. Patent Provisional Application No. 62 / 085,772 filed December 1, 2014 (Attorney Docket No. 59424); U.S. Patent Provisional Application No. 62 filed December 2, 2014 / 086,208 (Attorney Docket No. 61145); and U.S. Patent Provisional Application No. 62 / 164,710 (Attorney Docket No. 60652), filed May 21, 2015. The contents of all documents are hereby incorporated by reference as if fully set forth herein. technical field [0003] The present invention in some embodiments relates to pharmacology, and more particularly but not exclusively to methods, devices and systems for controlled pulmonary delivery of active agents. Background technique [0004] Natural substances, such as plant materials, provide a large numb...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61M11/04A61K9/00A61M15/00G16H40/60
CPCA61M11/042A61M15/002A61M15/0028A61M15/0045A61M15/005A61M16/20A61K31/05A61K31/352A61K31/465A61P1/00A61P1/04A61P1/08A61P1/14A61P9/10A61P9/12A61P11/00A61P11/06A61P13/10A61P15/00A61P17/02A61P17/04A61P19/02A61P21/00A61P25/00A61P25/04A61P25/08A61P25/14A61P25/16A61P25/18A61P25/20A61P25/22A61P25/24A61P25/30A61P25/32A61P27/06A61P29/00A61P31/04A61P31/14A61P31/18A61P35/00A61P35/02A61K9/007H05B1/0227A61M15/0066A61M2205/505A61M2205/332A61M2205/3375A61M2205/3313A61M2230/06A61M2230/30A61M2230/65A61M2230/205A61M2016/0039A61M2230/42A61M2230/50A61M2230/60A61M2230/63A61M15/0003A61K36/185A61M2016/0042A61M2205/70A61M2205/3592A61M2205/3561A61M2205/3553A61M2205/276A61M2230/005A24F40/51A24F40/53A24F40/60A24F40/65A61M2205/502A61M2205/3334A61M2205/3653A61M11/041A61M15/0001A61M15/0013A61M15/0015A61M15/0021A61M15/0051A61K9/0073A61K36/81A61M11/02A61M15/0065A61M15/0091A61M15/06A61M16/14A61M2205/0216A61M2205/3303A61M2205/3331A61M2205/3368A61M2205/3569A61M2205/36A61M2205/52H05B1/025
Inventor 佩利·大卫森希洛摩·欧模格赛斯·凯得勒
Owner SYQE医药有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com